Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

被引：0
|
作者：
Yoh Watanabe
Eiji Koike
Hidekatsu Nakai
Tomomaro Etoh
Hiroshi Hoshiai
机构：
[1] Kinki University School of Medicine,Department of Obstetrics and Gynecology
来源：
International Journal of Clinical Oncology | 2008年 / 13卷
关键词：
Recurrent ovarian cancer; Gemcitabine; Japanese patients; Platinum resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：345 / 348
页数：3
相关论文
共 50 条
  • [1] Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
    Watanabe, Yoh
    Koike, Eiji
    Nakai, Hidekatsu
    Etoh, Tomomaro
    Hoshiai, Hiroshi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 345 - 348
  • [2] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
    Adam, Jean-Philippe
    Boumedien, Feriel
    Letarte, Nathalie
    Provencher, Diane
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 47 - 53
  • [3] A phase II study of single agent gemcitabine in recurrent epithelial ovarian cancer
    Tay, SK
    Tan, PK
    Wong, L
    Wong, CB
    [J]. 7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 317 - 321
  • [4] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).
    Boumedien, Feriel
    Adam, Jean-Philippe
    Akkour, Khalid
    LeTarte, Nathalie
    Provencher, Diane M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment - Pooled Analysis of Phase II Trials
    Colombo, N.
    Del Campo, J. M.
    Sehouli, J.
    Sessa, C.
    Bidzinski, M.
    Nieto, A.
    Jiao, J.
    Kurzeder, C.
    Boman, K.
    Gonzalez-Martin, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S528 - S529
  • [6] Safety and efficacy outcomes in heavily and non-heavily pretreated patients with recurrent ovarian cancer (ROC) after single-agent trabectedin treatment: pooled analysis of phase II trials
    Kurzeder, C.
    Sehouli, J.
    Brugger, W.
    Zintl, P.
    De la Riba, M., I
    Kreienberg, R.
    [J]. ONKOLOGIE, 2011, 34 : 222 - 223
  • [7] Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma
    Piura, B
    Meirovitz, M
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2005, 26 (04) : 386 - 390
  • [8] A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
    Seiden, MV
    Gordon, AN
    Bodurka, DC
    Matulonis, UA
    Penson, RT
    Reed, E
    Alberts, DS
    Weems, G
    Cullen, M
    McGuire, WP
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 101 (01) : 55 - 61
  • [9] Single-agent oxaliplatin in pretreated advanced breast cancer patients:: A phase II study
    Garufi, C
    Nisticò, C
    Brienza, S
    Vaccaro, A
    D'Ottavio, A
    Zappalà, AR
    Aschelter, AM
    Terzoli, E
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (02) : 179 - 182
  • [10] TRABECTEDIN AS SINGLE-AGENT IN HEAVILY PRETREATED PATIENTS WITH RELAPSED OVARIAN CANCER (ROC): RESULTS FROM A RETROSPECTIVE STUDY
    Salutari, V.
    Ferrandina, G.
    Vincenzi, B.
    Marinaccio, M.
    Naglieri, E.
    Loizzi, V.
    Carpano, S.
    Lorusso, D.
    Masciullo, V.
    Scarciglia, M. L.
    Amadio, G.
    Tonini, G.
    Scambia, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
12345